{
  "source": "PA-Notification-Myalept.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1132-13\nProgram Prior Authorization/Notification\nMedication Myalept® (metreleptin)\nP&T Approval Date 5/2014, 5/2015, 5/2016, 5/2017, 5/2018, 5/2019, 5/2020, 5/2021, 5/2022,\n5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nMyalept (metreleptin) is a leptin analog indicated as an adjunct to diet as replacement therapy to treat\nthe complications of leptin deficiency in patients with congenital or acquired generalized\nlipodystrophy.\nLimitations of Use:\nThe safety and effectiveness of Myalept for the treatment of complications of partial lipodystrophy or\nfor the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been\nestablished. Myaept is not indicated for use in patients with HIV-related lipodystrophy or patients\nwith metabolic disease, without concurrent evidence of generalized lipodystrophy.\nDue to the risks associated with the development of anti-metreleptin antibodies that neutralize\nendogenous leptin and/or lymphoma, Myalept is only available through the Myalept Risk Evaluation\nand Mitigation Strategy (REMS) restricted program.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Myalept will be approved based on both of the following criteria:\na. Diagnosis of congenital or acquired generalized lipodystrophy associated with leptin\ndeficiency\n-AND-\nb. Myalept is being used as an adjunct to diet modification\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Myalept will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Myalept therapy\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\nb. Myalept is being used as an adjunct to diet modification\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may ap",
    "State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. Reference:\n1. Myalept [package insert]. Cary, NC: Chiesi USA, Inc.; March 2024.\nProgram Prior Authorization/Notification – Myalept® (metreleptin)\nChange Control\n5/2014 New program.\n5/2015 Annual review with no changes to coverage criteria. Updated\nreferences\n5/2016 Annual review. No changes to coverage criteria. Updated reference.\n5/2017 Annual review with no changes to coverage criteria.\n5/2018 Annual review with no changes to coverage criteria.\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n5/2019 Annual review. No changes to coverage criteria.\n5/2020 Annual review. Added information related to REMS program &\ncorrected trademark info\n5/2021 Annual review. No changes to coverage criteria. Updated reference.\n5/2022 Annual review. Updated reference.\n5/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n5/2024 Annual review with no changes to coverage criteria.\n5/2025 Annual review with no changes to coverage criteria. Updated\nbackground and reference.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}